Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

3.0%

5 terminated/withdrawn out of 166 trials

Success Rate

80.0%

-6.6% vs industry average

Late-Stage Pipeline

19%

32 trials in Phase 3/4

Results Transparency

5%

1 of 20 completed trials have results

Key Signals

48 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
52(39.1%)
N/A
26(19.5%)
Phase 1
22(16.5%)
Phase 3
22(16.5%)
Phase 4
10(7.5%)
Early Phase 1
1(0.8%)
133Total
Phase 2(52)
N/A(26)
Phase 1(22)
Phase 3(22)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (166)

Showing 20 of 166 trials
NCT06627712Phase 3Recruiting

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Role: collaborator

NCT07833657Phase 2Not Yet Recruiting

Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases

Role: collaborator

NCT06246344Phase 3Active Not Recruiting

Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Role: lead

NCT07808177Early Phase 1Recruiting

Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours

Role: lead

NCT07403370Completed

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Role: lead

NCT07062055Phase 2Recruiting

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Role: lead

NCT07137052Recruiting

Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma

Role: collaborator

NCT07686640Phase 3Recruiting

Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer

Role: lead

NCT07764523Not ApplicableNot Yet Recruiting

Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health

Role: collaborator

NCT07755917Not ApplicableNot Yet Recruiting

Preoperative Home-based Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health

Role: collaborator

NCT07304934Recruiting

A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer

Role: collaborator

NCT07683221Phase 2Not Yet Recruiting

SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

Role: lead

NCT07669051Phase 2Active Not Recruiting

A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

Role: lead

NCT04793672Completed

Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis

Role: collaborator

NCT07167342Phase 4Recruiting

The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

Role: collaborator

NCT05099848Phase 2Completed

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Role: lead

NCT07600268Phase 2Recruiting

Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer

Role: lead

NCT07173387Phase 2Active Not Recruiting

Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer

Role: lead

NCT07595107Not Yet Recruiting

Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer

Role: lead

NCT07026422Phase 2Recruiting

Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)

Role: lead